tbuckley/cabot-search huggingface dataset:
THE JARGON OF EDDYISM ET ID GENUS OMNE.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Oncology (2015)

Hereditary gastric cancer (HDGC) is associated with mutations in E-cadherin (CDH1), but there are some families that display the clinical characteristics of HDGC without carrying germline CDH1 mutations.Hansford et al performed extended mutational screening on 183 individuals meeting the criteria for HDGC.They found a diversity of CDH1 mutations, as well as mutations in other related genes.These data substantially expand our ability to identify families with a genetic predisposition to gastric cancer.Ford provides an Editorial.
Chronological improvement in long-term outcomes of surgical resection for patients with hepatocellular carcinoma: two large-volume center studies
Authors: Yun Bin Lee, Jeonghoon Lee, Hyo Young Lee, Cheol-Hyung Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Suk Kyun Hong, Eun Ju Cho, Su Jong Yu, Nam-Joon Yi, Kwang-Woong Lee, Jong Man Kim, Yoon Jun Kim, Kyung-Suk Suh, Jung-Hwan Yoon
Journal: Journal of Hepatology (2020)
Correction
Journal: BMJ (1983)

Snowdon awards for physically handicapped students Awards of up to C1000 a year for one to two years are offered to physically disabled young people for further education or training.The candidates must be over 17 and preferably under 25 years.They must have received an offer of further training and demonstrate that they are not only disabled but financially unable to take advantage of that offer.Last year 16 awards were made.Application forms and further information may be obtained from the secretary, Action Research for the Crippled Child, Vincent House, North Parade,
Las Psiconeurosis (Neurastenia, Histerismo, Psicastenia, Neurosis de Angustia, Etc.).
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A prevalent misconception regarding wide-complex tachycardias
Authors: F. Morady
Journal: JAMA (1985)

In response to a questionnaire, 59% of 196 physicians indicated that they were influenced by a patient's blood pressure and clinical status when attempting to distinguish ventricular tachycardia (VT) from paroxysmal supraventricular tachycardia with bundle-branch block. A sizable proportion of physicians are unaware that VT need not be associated with shock. More emphasis should be placed on making physicians aware that the differentiation of VT from paroxysmal supraventricular tachycardia should be based on electrocardiographic findings and not on the patient's blood pressure or clinical status. (<i>JAMA</i>1985;254:2790-2792)
Medical marijuana: a trial of science and politics
Authors: R. Voelker
Journal: JAMA (1994)

IN THE WORLD of community-based clinical trials, one of the goals is evaluating commonly used treatments, regardless of whether they're prescribed by physicians. Among those with HIV infection in San Francisco's Community Consortium, one such therapy is marijuana. For the past 2 years, Donald Abrams, MD, the consortium's chairman, has been trying to devise a trial to compare the efficacy of inhaled marijuana with dronabinol (Marinol, Roxane Laboratories Inc, Columbus, Ohio) as an appetite stimulant for patients with HIV wasting syndrome. Designing such a study to yield meaningful data is a trial in itself. Ushering it through a regulatory maze because it uses a schedule I controlled substance adds to the complexities. "It's difficult," says Abrams, also a professor of clinical medicine at the University of California-San Francisco. "If the science survives the politics, we'll be ready. But there are a lot of politics around this field. I want to
Urticaria
Authors: T. Zuberbier
Journal: Allergy (2003)

Urticaria has been known as a disease since antiquity. However, in the last decades an increasing understanding of the mechanisms involved in its pathogenesis has shown the high heterogeneity of different urticaria subtypes. Clear distinction of the subtypes is required not only to choose the correct measures in diagnosis and management, but also to interpret the available data in research. The subtypes can be grouped into spontaneous urticaria, which includes acute urticaria and chronic urticaria, the physical urticarias, special types of urticaria including, e.g. contact urticaria, and diseases related to urticaria for historical reasons, e.g. urticaria pigmentosa. Most urticaria subtypes have a profound impact on the quality of life and effective treatment is thus required in case the diagnostic procedures do not reveal a cause which can be treated. Although, for symptomatic relief, nonsedating H 1 ‐antihistamines are the first choice in most subtypes of urticaria, double‐blind controlled studies have shown that dosages required may exceed those recommended for other diseases, e.g. allergic rhinitis. Alternative treatments should be reserved for unresponsive patients.
Osteopathy.
Authors: E. F. Wakefield
Journal: JAMA (1905)

Cleveland, Ohio, March 22, 1905. <h3>To the Editor:</h3> —I have noticed that in articles relative to osteopathy, the profession makes the claim that it is "massage" or "Swedish movements" or something akin to these, and that the osteopath as specifically denies this and says that, although there is a similarity in these various systems of mechanotherapy and osteopathy, yet "there is a difference essential in kind and fundamental in importance." His statement is probably not true, but the question as to what osteopathy is does not seem to be the essential point to determine, but rather what is the value of his method. If it is a worthy system of healing it should be recognized and used, while if its claims are false it is criminal to allow the practice. The followers of this "school" affirm that "osteopathy is still in its infancy," and yet they claim that nearly or
Preserving the physician-patient relationship in the era of managed care
Authors: E. J. Emanuel
Journal: JAMA (1995)

Even without comprehensive health care reform legislation, the US health care system is undergoing significant changes. Probably the most important change is the expansion of managed care with significant price competition. One of the major concerns about this change is the effect of managed care on the physician-patient relationship. To provide a normative standard for evaluating the effect of changes, we need an ideal conception of the physician-patient relationship. This ideal can be summarized by six C's: choice, competence, communication, compassion, continuity, and (no) conflict of interest. For the 37 million uninsured Americans there is little chance of realizing the ideal physician-patient relationship, since they lack the choice of practice setting and physician, receive care in a rushed atmosphere that undermines communication and compassion, and have no continuity of care. While many insured Americans may believe they have an ideal physician-patient relationship, the relationship is threatened by lack of a regular assessment of competence, by financial incentives that undermine good communication, and by the persistence of conflict of interest. The shift to managed care may improve the choice of practice settings, especially in sections of the country that currently lack managed care; increase choice of preventive services; make quality assessments more routine; and improve communication by making greater use of primary care physicians and nonphysician providers. However, the expansion of managed care and the imposition of significant cost control have the potential to undermine all aspects of the ideal physician-patient relationship. Choice could be restricted by employers and by managed care selection of physicians; poor quality indicators could undermine assessments of competence; productivity requirements could eliminate time necessary for communication; changing from one to another managed care plan to secure the lowest costs could produce significant disruption in continuity of care; and use of salary schemes that reward physicians for not using medical services could increase conflict of interest. (<i>JAMA</i>. 1995;273:323-329)
Methods for Reducing Lead Exposure in Young Children and Other Risk Groups: An Integrated Summary of a Report to the U.S. Congress on Childhood Lead Poisoning
Authors: Paul Mushak, Annemarie F. Crocetti
Journal: Environmental Health Perspectives (1990)

As part of a Congressionally mandated report on U.S. childhood lead poisoning prepared by the Federal government (U.S. Agency for Toxic Substances and Disease Registry [ATSDR]), the authors have analyzed the relative effectiveness of measures to reduce source-specific lead exposure of U.S. children. An integrated overview of this analysis is presented in this article. Two national actions, the Federally mandated phasedown of lead in gasoline by the U.S. Environmental Protection Agency and the voluntary phasedown of lead use in domestic food can production, are examples of centrally directed initiatives that have been relatively successful in limiting childhood lead exposure in the U.S. Efforts to abate lead-based paint exposure of children have largely failed. This is especially true for the nation's 21 million residential units with the highest lead content paint. Similarly, abatement of lead exposure from contaminated dusts and soils has generally been unsuccessful. Comprehensive measures to reduce lead exposure from drinking water in residences and public facilities, e.g., elementary schools, are only now being promulgated or implemented. The full extent of their effectiveness remains to be demonstrated. There are many miscellaneous but potentially severe exposure sources that are difficult to control but require attention, such as poorly glazed foodware and ethno-specific preparations.
PWE-113 Coeliac serology at a large district general hospital, results in 6394 patients
Authors: K Kodjabashia, S A Haider, C Crossland, V Lashmar, S D McLaughlin
Journal: Gut (2012)

<h3>Introduction</h3> Coeliac disease has an estimated UK prevalence of 1% and is an important, common cause of many gastro-intestinal and non-gastro-intestinal symptoms. Coeliac serological blood tests are commonly performed in both primary and secondary care. Positive coeliac serology occurs in patients with: (i) Coeliac disease, (ii) Latent Coeliac disease, (iii) Dermatitis herpetiformis. The UK national institute for health and clinical excellence (NICE),<sup>1</sup> British society of gastroenterology guidelines (BSG) and American Gastroenterology Association (AGA)<sup>2</sup> guidelines recommend that all patients with positive coeliac serology undergo duodenal biopsy since diagnosis of coeliac disease requires both positive serology and typical histological findings. <h3>Methods</h3> We reviewed the results of all coeliac serology tests performed at our hospital laboratory in the previous 12 months. The case notes for all patients with positive results were reviewed. <h3>Results</h3> 6394 endomysial antibody results were performed on adult patients between 1 October 2010 and 30 September 2011. 100 (1.6%) were positive. Of these 67 (67.0%) underwent biopsy. 50 (74.6%) had histological evidence of coeliac disease; 5 (7.5%) were inconclusive and 11 (16.4%) had no evidence of coeliac disease. Of those who did not undergo biopsy 11 (33.0%) were known to have CD or refused D2 biopsy. In 22 (21.6%) patients gastroenterological follow-up had not been arranged, of these 16 (72.7%) tests had been arranged in primary care. <h3>Conclusion</h3> In this study 1.6% of those tested had serology suggestive of coeliac disease, this is marginally larger than expected by chance and suggests that testing was not appropriately targeted. Surprisingly 21.6% of positive tests did not have appropriate follow-up arranged. We suspect these findings are not confined to our institution. Our findings suggest that engagement and education of non-gastroenterology colleagues, particularly those in primary care is important in order that patients receive appropriate treatment and conform to AGA, BSG and NICE guidelines. We plan in future that all positive coeliac serology test reports be issued with the advice that referral to a gastroenterologist is recommended. <h3>Competing interests</h3> None declared. <h3>References</h3> 1. <b>AG1</b>. <i>Recognition and Assessment of Coeliac Disease, Clinical Guidelines, CG 86</i>. Issued: May 2009. 2. <b>AGA Institute</b>. AGA Institute medical position statement on the diagnosis and management of coeliac disease. <i>Gastroenterology</i> 2006;<b>131</b>:1997–80.
Textbook of Medical Treatment by Various Authors
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.
Authors: Mingzhu Huang, Zhiyu Chen, Yusheng Wang, Xiaodong Zhu, Wen Zhang, Xiaowei Zhang, Xiaoying Zhao, Lixin Qiu, Chenchen Wang, Weijian Guo
Journal: Journal of Clinical Oncology (2018)

e15558 Background: The FOLFOX regimen consisting of fluorouracil (5-FU) and oxaliplatin, and the FOLFIRI regimen consisting of 5-FU and irinotecan serve as either first- or second-line treatment for metastatic colorectal cancer (mCRC), and there is no third-line chemotherapy regimen after failure of 5-FU, oxaliplatin, and irinotecan. Studies have shown that raltitrexed or S-1 has no complete cross-resistance with 5-FU and may be used for mCRC after failure of 5-FU. In the present study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 in the treatment of mCRC after failure of conventional chemotherapy. Methods: Up to November 2017, thirty-five patients with mCRC treated with raltitrexed combined with S-1 after failure of fluorouracil, oxaliplatin and irinotecan were included in this study. Raltitrexed (3 mg/m2) intravenous infusion was given on the first day, and the administration of S-1 (daily dose according to body surface area (BSA): 100 mg/day when BSA ≥1.25 m2 to < 1.5 m2; 120 mg/day when BSA≥1.5 m2) continued for 2 weeks, and stopped for one week. The regimen was repeated every 3 weeks. Tumor response was evaluated according to RECIST 1.1 criteria. Toxicity was graded according to NCI-CTC 4.0 version. Results: Among 35 patients, 2 had PR, 18 had SD, and 15 had PD. The ORR (objective response rate) was 5.7%, and the DCR (disease control rate) was 51.4%. The median PFS (progression free survival) was 3.0 months. Adverse reactions included fatigue, abnormal liver enzymes, neutropenia, stomatitis, pyrexia, arrhythmia, hypertension, diarrhea, nausea and most of these were grade 1-2. Conclusions: The combination of raltitrexed and S-1, both of which targeting TS, preliminarily showed promising effects for metastatic colorectal cancer after failure of standard chemotherapy and may be used as third-line treatment regimen. Clinical trial information: NCT02618356.
Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.
Authors: Firas Abdollah, Deepansh Dalela, Maria Santiago-Jimenez, Kasra Yousefi, Jeffrey Karnes, Ashley Ross, Robert B. Den, Stephen J. Freedland, Edward M. Schaeffer, Adam Dicker, Alberto Briganti, Elai Davicioni, Mani Menon
Journal: Journal of Clinical Oncology (2017)

142 Background: Despite documented oncological benefit, postoperative adjuvant radiotherapy (aRT) utilization in prostate cancer (PCa) patients is still limited in the US. We aimed to develop and internally validate a risk stratification tool incorporating the Decipher score, along with routinely available clinicopathologic features, to identify patients who would benefit the most from aRT. Methods: Our cohort included a total of 512 PCa patients treated with RP at one of four US academic centers between 1990-2010. All patients had ≥ pT3a disease, positive margins, and/or pathologic lymph node invasion (LNI). Multivariable Cox regression analysis (MVA) tested the relationship between available predictors (including Decipher score) and clinical recurrence (CR), which were then used to develop a novel risk stratification tool. Our study adhered to the TRIPOD guidelines for development of prognostic models. Results: Overall, 21.9% patients received aRT. Median follow-up in censored patients was 8.3 years. The 10-year CR rate was 4.9% vs. 17.4% in patients treated with aRT vs. initial observation (p &lt; 0.001). Pathological T3b/T4 stage, Gleason score 8-10, LNI and Decipher score &gt; 0.6 were independent predictors of CR (all p &lt; 0.01) Cumulative number of risk factors was 0, 1, 2, and 3-4 in respectively 46.5, 28.9, 17.2, and 7.4% of patients. Adjuvant RT was associated with decreased CR rate in patients with ≥ 2 risk factors (10-year CR rate 10.1% in aRT vs. 42.1% in initial observation, p = 0.008), but not in those with &lt; 2 risk factors (p = 0.23). Conclusions: Utilizing the novel model to indicate aRT might reduce overtreatment, decrease unnecessary side effects, and reduce risk of CR in the subset of patients (~25% of all patients with aggressive pathological disease) who really benefit from this therapy.
Trisomy of Chromosome #13 in Spontaneous Mammary Tumors of GR, C3H, and Noninbred Swiss Mice: Reply
Authors: Ryuichi Dofuku
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Trisomy of Chromosome #13 in Spontaneous Mammary Tumors of GR, C3H, and Noninbred Swiss Mice: Reply Get access Ryuichi Dofuku, M.D. Ryuichi Dofuku, M.D. Cell Biology Cancer Institute Japanese Foundation for Cancer Research Kami-Ikebukuro, Toshima-ku Tokyo 108, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 65, Issue 4, October 1980, Pages 668–669, https://doi.org/10.1093/jnci/65.4.668-a Published: 01 October 1980
Letter: Popliteal cyst
Journal: JAMA (1975)

<h3>To the Editor.—</h3> I enjoyed reading Dr. Hussey's editorial "Popliteal Cyst: Diagnostic Dilemmas" (230:589, 1974) but believe his last paragraph requires some comments. Having had considerable experience with both elective and emergency surgery on popliteal aneurysms, I would strongly advise that this diagnosis not be made by the insertion of an exploring needle into the lump. Bleeding might be difficult to stop and the usually present clot might be dislocated. If there is strong suspicion of a popliteal aneurysm, careful clinical examination and possibly an arteriogram will always make the diagnosis. Dr. Singer is probably right, especially as regards dislodgement of a clot from an aneurysm that does not exhibit a definite expansile pulsation. I must have been lucky years ago.
Increased resistance to ischaemic injury in the isolated perfused atherosclerotic heart of the cholesterol-fed rabbit
Authors: B. Le Grand, B. Vie, P. Faure, A.-D. Degryse, P. Mouillard, G. W. John
Journal: Cardiovascular Research (1995)

Journal Article Increased resistance to ischaemic injury in the isolated perfused atherosclerotic heart of the cholesterol-fed rabbit Get access Bruno Le Grand, Bruno Le Grand aaCentre de Recherche Pierre Fabre, Division of Cardiovascular Diseases, 17, Ave. Jean Moulin, 81100 Castres, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Bruno Vié, Bruno Vié aaCentre de Recherche Pierre Fabre, Division of Cardiovascular Diseases, 17, Ave. Jean Moulin, 81100 Castres, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Philippe Fauré, Philippe Fauré bbCentre d'Anatomie et de Cytologie Pathologiques, 47 rue Théron Périé, 81100 Castres, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Anne-Dominique Degryse, Anne-Dominique Degryse bbCentre d'Anatomie et de Cytologie Pathologiques, 47 rue Théron Périé, 81100 Castres, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Pierre Mouillard, Pierre Mouillard Search for other works by this author on: Oxford Academic PubMed Google Scholar Gareth W. John Gareth W. John * *Corresponding author. Tel.: (+ 33-63) 71 42 04; fax: (+ 33-63) 71 42 99. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 30, Issue 5, November 1995, Pages 689–696, https://doi.org/10.1016/S0008-6363(95)00076-3 Published: 01 November 1995 Article history Received: 10 January 1995 Accepted: 05 May 1995 Published: 01 November 1995